newsfilter
← Latest News
Business Wire·

Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders

Ipsen obtains exclusive options to Spherical Nucleic Acids (SNAs™) currently under discovery evaluation for Huntington's disease and Angelman syndrome Exicure will be responsible for discovery and certain pre-clinical development activities. In